Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Escherichia coli F18ab fimbriae are surface structures expressed by certain strains of E. coli, particularly STEC strains. These fimbriae mediate bacterial adhesion to host intestinal cells, playing a crucial role in colonization and pathogenesis of edema disease in weaned piglets. They are often co-expressed with Shiga toxin 2e (Stx2e), which contributes to the vascular damage characteristic of the disease. The major subunit gene is fedA, and differentiation from the related F18ac variant can be achieved through molecular techniques like PCR-RFLP or sequencing of fedA. Flagella can also contribute to virulence during infection.
Antibodies against F18ab fimbriae prevent bacterial adhesion to intestinal cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Escherichia coli F18ab fimbriae (F18ab).